Literature DB >> 23300370

Report from the 13th annual Western canadian gastrointestinal cancer consensus conference; calgary, alberta; september 8-10, 2011.

M M Vickers1, J Pasieka, E Dixon, S McEwan, A McKay, D Renouf, D Schellenberg, D Ruether.   

Abstract

The 13th annual Western Canadian Gastrointestinal Cancer Consensus Conference was held in Calgary, Alberta, September 8-10, 2011. Health care professionals involved in the care of patients with gastrointestinal cancers participated in presentation and discussion sessions for the purposes of developing the recommendations presented here. This consensus statement addresses current issues in the management neuroendocrine tumours and locally advanced pancreatic cancer.

Entities:  

Keywords:  Neuroendocrine tumours; pancreatic cancer; radiation; systemic therapy

Year:  2012        PMID： 23300370      PMCID： PMC3503677          DOI： 10.3747/co.19.1167

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


  84 in total

1.  Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I.

Authors:  M N Pollak; C Polychronakos; H Guyda
Journal:  Anticancer Res       Date:  1989 Jul-Aug       Impact factor: 2.480

2.  Ampullary somatostatinoma associated with von Recklinghausen's neurofibromatosis presenting as obstructive jaundice.

Authors:  C C Tan; R I Hall; D Semeraro; R P Irons; J G Freeman
Journal:  Eur J Surg Oncol       Date:  1996-06       Impact factor: 4.424

3.  Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals.

Authors:  Terence O'Reilly; Paul Mj McSheehy
Journal:  Transl Oncol       Date:  2010-04       Impact factor: 4.243

Review 4.  Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook.

Authors:  B Eriksson; K Oberg
Journal:  Ann Oncol       Date:  1999       Impact factor: 32.976

5.  Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients.

Authors:  Mukund S Didolkar; Cardella W Coleman; Mark J Brenner; Kyo U Chu; Nicole Olexa; Elizabeth Stanwyck; Airong Yu; Nagaraj Neerchal; Stuart Rabinowitz
Journal:  J Gastrointest Surg       Date:  2010-09-14       Impact factor: 3.452

Review 6.  Neuroendocrine tumors. Biotherapy.

Authors:  U Plöckinger; B Wiedenmann
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2007-03       Impact factor: 4.690

7.  Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar
Journal:  J Clin Oncol       Date:  2007-04-23       Impact factor: 44.544

8.  Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system.

Authors:  A Chaudhry; V Papanicolaou; K Oberg; C H Heldin; K Funa
Journal:  Cancer Res       Date:  1992-02-15       Impact factor: 12.701

9.  Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

Authors:  James C Yao; Alexandria T Phan; David Z Chang; Robert A Wolff; Kenneth Hess; Sanjay Gupta; Carmen Jacobs; Jeannette E Mares; Andrea N Landgraf; Asif Rashid; Funda Meric-Bernstam
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

Review 10.  Targeting the mTOR signaling network for cancer therapy.

Authors:  Funda Meric-Bernstam; Ana Maria Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2009-03-30       Impact factor: 44.544
View more
  1 in total

1.  Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.

Authors:  Carmel Jacobs; Ian D Graham; Julie Makarski; Michaël Chassé; Dean Fergusson; Brian Hutton; Mark Clemons
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.